JP2013107903A5 - - Google Patents

Download PDF

Info

Publication number
JP2013107903A5
JP2013107903A5 JP2013045053A JP2013045053A JP2013107903A5 JP 2013107903 A5 JP2013107903 A5 JP 2013107903A5 JP 2013045053 A JP2013045053 A JP 2013045053A JP 2013045053 A JP2013045053 A JP 2013045053A JP 2013107903 A5 JP2013107903 A5 JP 2013107903A5
Authority
JP
Japan
Prior art keywords
bis
composition
phenylene
methylene
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013045053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013107903A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013107903A publication Critical patent/JP2013107903A/ja
Publication of JP2013107903A5 publication Critical patent/JP2013107903A5/ja
Pending legal-status Critical Current

Links

JP2013045053A 2005-08-19 2013-03-07 化学療法の強化方法 Pending JP2013107903A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70997805P 2005-08-19 2005-08-19
US60/709,978 2005-08-19
US73473605P 2005-11-08 2005-11-08
US60/734,736 2005-11-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008527219A Division JP2009504788A (ja) 2005-08-19 2006-08-21 化学療法の強化方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013169087A Division JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Publications (2)

Publication Number Publication Date
JP2013107903A JP2013107903A (ja) 2013-06-06
JP2013107903A5 true JP2013107903A5 (https=) 2013-10-03

Family

ID=37758501

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008527219A Pending JP2009504788A (ja) 2005-08-19 2006-08-21 化学療法の強化方法
JP2013045053A Pending JP2013107903A (ja) 2005-08-19 2013-03-07 化学療法の強化方法
JP2013169087A Pending JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008527219A Pending JP2009504788A (ja) 2005-08-19 2006-08-21 化学療法の強化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013169087A Pending JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Country Status (9)

Country Link
US (1) US20070043012A1 (https=)
EP (1) EP1951046B1 (https=)
JP (3) JP2009504788A (https=)
CN (1) CN101365336B (https=)
AU (1) AU2006280945A1 (https=)
BR (1) BRPI0615180A2 (https=)
CA (1) CA2619828A1 (https=)
IL (1) IL189599A0 (https=)
WO (1) WO2007022523A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) * 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
WO2008075371A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
US20110207814A1 (en) * 2009-12-23 2011-08-25 Pranela Rameshwar Combination Therapy for Breast Cancer Treatment
AU2011300818B2 (en) * 2010-09-09 2015-11-12 TME Pharma AG SDF-1 binding nucleic acids and the use thereof in cancer treatment
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
JP6294459B2 (ja) 2013-03-24 2018-03-14 バイオカイン・セラピューティクス・リミテッドＢｉｏｋｉｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ． 骨髄性白血病の処置方法
ES2811804T3 (es) 2013-10-31 2021-03-15 Biokine Therapeutics Ltd Un inhibidor peptídico de CXCR4 para su uso en el tratamiento de la leucemia mieloide aguda con una mutación de FLT3
EP3125919A4 (en) * 2014-02-19 2018-01-03 Microconstants China Inc. Chemokine receptor antagonist and its combinational therapy
WO2016114634A2 (ko) * 2015-01-16 2016-07-21 서울대학교 산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
KR101759688B1 (ko) * 2015-01-16 2017-07-20 서울대학교산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
WO2016176155A1 (en) 2015-04-25 2016-11-03 Poznansky Mark C Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
EP3302710A4 (en) * 2015-06-03 2019-02-20 The University of Queensland MOBILIZERS AND USE THEREOF
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
AU2016324303A1 (en) * 2015-09-18 2018-04-26 The General Hospital Corporation Dba Massachusetts General Hospital Modified T-cells having anti-fugetactic properties and uses thereof
CN109069426B (zh) * 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20210338767A1 (en) 2018-09-25 2021-11-04 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
TWI781469B (zh) * 2020-10-27 2022-10-21 行政院原子能委員會核能研究所 複合物、造影劑及治療與cxcr4接受體相關疾病的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005204A (en) * 1973-03-23 1977-01-25 Burroughs Wellcome Co. Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
AU2334301A (en) * 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
HK1052011A1 (zh) 2000-09-15 2003-08-29 Anormed Inc. 趋化因子受体结合杂环化合物
US6734191B2 (en) 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DE60137435D1 (de) 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
CA2431611A1 (en) 2001-01-23 2002-08-01 P&G-Clairol, Inc. Primary intermediates for oxidative coloration of hair
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
DK1411918T3 (da) * 2001-07-31 2012-04-23 Genzyme Global S A R L Fremgangsmåder til at mobilisere progenitor/stamceller
PL369856A1 (en) 2001-12-21 2005-05-02 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
JP2006524242A (ja) 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
US20040202935A1 (en) 2003-04-08 2004-10-14 Jeremy Barker Cathode active material with increased alkali/metal content and method of making same
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
CA2643209A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration

Similar Documents

Publication Publication Date Title
JP2013107903A5 (https=)
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
JP2013107903A (ja) 化学療法の強化方法
JP2022520061A5 (https=)
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP2017519753A5 (https=)
JP2020097577A5 (https=)
AU2016363591B2 (en) Melflufen dosage regimens for cancer
JP2016515110A5 (https=)
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
JP5113038B2 (ja) 癌治療用キットおよび癌治療用医薬組成物
WO2011159100A2 (ko) 항암 활성을 나타내는 약제학적 조성물
JP2012502915A5 (https=)
JP2014521641A5 (https=)
JP2016515550A5 (https=)
JP2008540505A5 (https=)
JP2014148552A5 (https=)
SI2847204T1 (en) Sterol derivatives and their use for the treatment of diseases involving the transformation of astrocytic cells or the treatment of malignant haemopathies
JP2016501208A5 (https=)
HRP20191322T1 (hr) Antitumorska kombinacija koja sadži kabazitaksel i cisplatin
RU2017125150A (ru) Фармацевтическая композиция для лечения или создания условий ремиссии у пожилого пациента с раком или у пациента на терминальной стадии рака
CN103417977A (zh) 叶酸受体α亚型高效介导的靶向投药系统
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
JP2019525924A5 (https=)